Pricey Cures Pose Reinsurance, Cost-Sharing Challenges

Genomic, curative drugs for chronic and terminal diseases are perhaps the most exciting new treatments in medicine. But even though these highly tailored therapies come to market with the potential to save costs for the health care system, the industry is struggling to pay for them because of their high up front costs. One expert says that PBMs are well-positioned to sit at the center of new financial models that distribute the high cost and substantial savings equitably across the entire industry.

“The key drug, device and diagnostic access decision-makers have oftentimes utilized traditional health economics approaches to assessing value of health care products and services. That said, value can mean different things to different decision-makers, and that’s an important distinction to make,” said Brian Leinwand, an associate principal for health economics at Avalere Health, during a June 9 webinar on alternative financing models for emergent therapies.

© 2022 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

white-house
May 26

Biden Administration Has Options for Drug Pricing Reform

READ MORE
pharmacist-and-patient
May 26

Court Decision on Accumulator Rule Could Encourage State Bans

READ MORE
doctor-and-infusion-patient
May 26

Third-Party Care Pathways Gain Steam as Cancer Costs Rise

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today